Literature DB >> 32770196

Mucosal Inflammatory and Wound Healing Gene Programs Reveal Targets for Stricturing Behavior in Pediatric Crohn's Disease.

Yael Haberman1,2, Phillip Minar1, Rebekah Karns1, Phillip J Dexheimer1, Sudhir Ghandikota3, Samuel Tegge1, Daniel Shapiro1, Brianne Shuler1, Suresh Venkateswaran4, Tzipi Braun2, Allison Ta1, Thomas D Walters5, Robert N Baldassano6, Joshua D Noe7, Joel Rosh8, James Markowitz9, Jennifer L Dotson10, David R Mack11, Richard Kellermayer12, Anne M Griffiths5, Melvin B Heyman13, Susan S Baker14, Dedrick Moulton15, Ashish S Patel16, Ajay S Gulati17, Steven J Steiner18, Neal LeLeiko19, Anthony Otley20, Maria Oliva-Hemker21, David Ziring22, Ranjana Gokhale23, Sandra Kim24, Stephen L Guthery25, Stanley A Cohen26, Scott Snapper27, Bruce J Aronow1, Michael Stephens28, Greg Gibson29, Jonathan R Dillman1, Marla Dubinsky30, Jeffrey S Hyams31, Subra Kugathasan4, Anil G Jegga1, Lee A Denson1.   

Abstract

BACKGROUND AND AIMS: Ileal strictures are the major indication for resective surgery in Crohn's disease (CD). We aimed to define ileal gene programs present at diagnosis linked with future stricturing behavior during five year follow-up, and to identify potential small molecules to reverse these gene signatures.
METHODS: Antimicrobial serologies and pre-treatment ileal gene expression were assessed in a representative subset of 249 CD patients within the RISK multicenter pediatric CD inception cohort study, including 113 that are unique to this report. These data were used to define genes associated with stricturing behavior and for model testing to predict stricturing behavior. A bioinformatics approach to define small molecules which may reverse the stricturing gene signature was applied.
RESULTS: 19 of the 249 patients developed isolated B2 stricturing behavior during follow-up, while 218 remained B1 inflammatory. Using deeper RNA sequencing than in our prior report, we have now defined an inflammatory gene signature including an oncostatin M co-expression signature, tightly associated with extra-cellular matrix (ECM) gene expression in those who developed stricturing complications. We further computationally prioritize small molecules targeting macrophage and fibroblast activation and angiogenesis which may reverse the stricturing gene signature. A model containing ASCA and CBir1 serologies and a refined eight ECM gene set was significantly associated with stricturing development by year five after diagnosis (AUC (95th CI) = 0.82 (0.7-0.94)).
CONCLUSION: An ileal gene program for macrophage and fibroblast activation is linked to stricturing complications in treatment naïve pediatric CD, and may inform novel small molecule therapeutic approaches.
© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ileum; pediatric Crohn Disease; small molecule; surgery; transcriptome

Year:  2020        PMID: 32770196      PMCID: PMC7904088          DOI: 10.1093/ecco-jcc/jjaa166

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  44 in total

1.  Fiji: an open-source platform for biological-image analysis.

Authors:  Johannes Schindelin; Ignacio Arganda-Carreras; Erwin Frise; Verena Kaynig; Mark Longair; Tobias Pietzsch; Stephan Preibisch; Curtis Rueden; Stephan Saalfeld; Benjamin Schmid; Jean-Yves Tinevez; Daniel James White; Volker Hartenstein; Kevin Eliceiri; Pavel Tomancak; Albert Cardona
Journal:  Nat Methods       Date:  2012-06-28       Impact factor: 28.547

2.  PPARalpha activators inhibit tissue factor expression and activity in human monocytes.

Authors:  N Marx; N Mackman; U Schönbeck; N Yilmaz; V Hombach; P Libby; J Plutzky
Journal:  Circulation       Date:  2001-01-16       Impact factor: 29.690

3.  Luminally polarized mural and vascular remodeling in ileal strictures of Crohn's disease.

Authors:  Xiaofei Zhang; Huaibin Mabel Ko; Joana Torres; Hinaben J Panchal; Zhenjian Cai; Mathilde Wagner; Bruce E Sands; Jean-Frederic Colombel; Judy Cho; Bachir Taouli; Noam Harpaz
Journal:  Hum Pathol       Date:  2018-03-16       Impact factor: 3.466

4.  Prostaglandin E2 promotes wound-induced migration of intestinal subepithelial myofibroblasts via EP2, EP3, and EP4 prostanoid receptor activation.

Authors:  Koichi Iwanaga; Muneyoshi Okada; Takahisa Murata; Masatoshi Hori; Hiroshi Ozaki
Journal:  J Pharmacol Exp Ther       Date:  2011-12-02       Impact factor: 4.030

5.  Peroxisome proliferators alter lipid acquisition and elastin gene expression in neonatal rat lung fibroblasts.

Authors:  S E McGowan; S K Jackson; M M Doro; P J Olson
Journal:  Am J Physiol       Date:  1997-12

6.  Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts.

Authors:  Caroline Ospelt; Joachim C Mertens; Astrid Jüngel; Fabia Brentano; Hanna Maciejewska-Rodriguez; Lars C Huber; Hossein Hemmatazad; Thomas Wüest; Alexander Knuth; Renate E Gay; Beat A Michel; Steffen Gay; Christoph Renner; Stefan Bauer
Journal:  Arthritis Rheum       Date:  2010-05

7.  ToppCluster: a multiple gene list feature analyzer for comparative enrichment clustering and network-based dissection of biological systems.

Authors:  Vivek Kaimal; Eric E Bardes; Scott C Tabar; Anil G Jegga; Bruce J Aronow
Journal:  Nucleic Acids Res       Date:  2010-05-19       Impact factor: 16.971

8.  Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.

Authors:  Thomas D Walters; Mi-Ok Kim; Lee A Denson; Anne M Griffiths; Marla Dubinsky; James Markowitz; Robert Baldassano; Wallace Crandall; Joel Rosh; Marian Pfefferkorn; Anthony Otley; Melvin B Heyman; Neal LeLeiko; Susan Baker; Stephen L Guthery; Jonathan Evans; David Ziring; Richard Kellermayer; Michael Stephens; David Mack; Maria Oliva-Hemker; Ashish S Patel; Barbara Kirschner; Dedrick Moulton; Stanley Cohen; Sandra Kim; Chunyan Liu; Jonah Essers; Subra Kugathasan; Jeffrey S Hyams
Journal:  Gastroenterology       Date:  2013-10-23       Impact factor: 22.682

9.  Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Authors:  Nathaniel R West; Ahmed N Hegazy; Benjamin M J Owens; Samuel J Bullers; Bryan Linggi; Sofia Buonocore; Margherita Coccia; Dieter Görtz; Sébastien This; Krista Stockenhuber; Johanna Pott; Matthias Friedrich; Grigory Ryzhakov; Frédéric Baribaud; Carrie Brodmerkel; Constanze Cieluch; Nahid Rahman; Gerhard Müller-Newen; Raymond J Owens; Anja A Kühl; Kevin J Maloy; Scott E Plevy; Satish Keshav; Simon P L Travis; Fiona Powrie
Journal:  Nat Med       Date:  2017-04-03       Impact factor: 53.440

10.  Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.

Authors:  Sanjay K Murthy; Jahanara Begum; Eric I Benchimol; Charles N Bernstein; Gilaad G Kaplan; Jeffrey D McCurdy; Harminder Singh; Laura Targownik; Monica Taljaard
Journal:  Gut       Date:  2019-06-12       Impact factor: 23.059

View more
  7 in total

Review 1.  The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease.

Authors:  Christopher A Lamb; Aamir Saifuddin; Nick Powell; Florian Rieder
Journal:  Gastroenterology       Date:  2022-01-04       Impact factor: 22.682

2.  Eicosatetraynoic Acid and Butyrate Regulate Human Intestinal Organoid Mitochondrial and Extracellular Matrix Pathways Implicated in Crohn's Disease Strictures.

Authors:  Ingrid Jurickova; Erin Bonkowski; Elizabeth Angerman; Elizabeth Novak; Alex Huron; Grayce Akers; Kentaro Iwasawa; Tzipi Braun; Rotem Hadar; Maria Hooker; Sarah Han; David J Cutler; David T Okou; Subra Kugathasan; Anil Jegga; James Wells; Takanori Takebe; Kevin P Mollen; Yael Haberman; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2022-07-01       Impact factor: 7.290

3.  Paediatric Ulcerative Colitis Is a Fibrotic Disease and Is Linked with Chronicity of Inflammation.

Authors:  Ilyssa O Gordon; Suha Abushamma; Jacob A Kurowski; Stefan D Holubar; Lei Kou; Ruishen Lyu; Florian Rieder
Journal:  J Crohns Colitis       Date:  2022-06-24       Impact factor: 10.020

4.  Association of Baseline Luminal Narrowing With Ileal Microbial Shifts and Gene Expression Programs and Subsequent Transmural Healing in Pediatric Crohn Disease.

Authors:  Allison D Ta; Nicholas J Ollberding; Rebekah Karns; Yael Haberman; Adina L Alazraki; David Hercules; Robert Baldassano; James Markowitz; Melvin B Heyman; Sandra Kim; Barbara Kirschner; Jason M Shapiro; Joshua Noe; Maria Oliva-Hemker; Anthony Otley; Marian Pfefferkorn; Richard Kellermayer; Scott Snapper; Shervin Rabizadeh; Ramnik Xavier; Marla Dubinsky; Jeffrey Hyams; Subra Kugathasan; Anil G Jegga; Jonathan R Dillman; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2021-10-20       Impact factor: 5.325

5.  Expression of Fibrosis-Related Genes in Liver and Kidney Fibrosis in Comparison to Inflammatory Bowel Diseases.

Authors:  Miha Jerala; Nina Hauptman; Nika Kojc; Nina Zidar
Journal:  Cells       Date:  2022-01-18       Impact factor: 6.600

Review 6.  Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD.

Authors:  Nurulamin M Noor; Paula Sousa; Stéphane Paul; Xavier Roblin
Journal:  Inflamm Bowel Dis       Date:  2022-08-01       Impact factor: 7.290

Review 7.  Mechanism of fibrosis and stricture formation in Crohn's disease.

Authors:  Johannes Alfredsson; Mary Jo Wick
Journal:  Scand J Immunol       Date:  2020-12       Impact factor: 3.487

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.